(Press-News.org) HOUSTON and MILAN ― The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Under the agreement, Sibylla and MD Anderson will jointly conduct discovery and development work from target identification through drug candidate nomination on selected proteins, with the potential to continue further pre-clinical and clinical development. The collaboration brings together Sibylla’s Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology with the drug development expertise and capabilities of MD Anderson’s Therapeutics Discovery division.
“The Sibylla team is committed to expanding the applications of our PPI-FIT technology and FIDs to provide new treatment options for hard-to-treat indications. This collaboration builds upon the progress we have achieved to date and the applicability of our technology and know-how,” said Lidia Pieri, PhD, co-founder and chief executive officer of Sibylla Biotech. “We value the opportunity to work with MD Anderson’s team of drug development experts in order to foster our vision of treating patients with high unmet medical need.”
Sibylla’s proprietary PPI-FIT technology is used to discover and develop FIDs, small molecules that induce the degradation of target proteins by interfering with the folding pathway. Notably, PPI-FIT can be applied to target proteins currently considered “undruggable” due to the absence of suitable pockets in their native state.
“Folding interfering degraders represent an exciting new modality to target key cancer drivers, and we look forward to opportunities to advance compelling candidates forward as novel therapeutic options,” said Tim Heffernan, Ph.D., vice president and head of Therapeutics Discovery at MD Anderson. “By aligning Sibylla’s innovative PPI-FIT technology with our drug development engine, we hope to create impactful new medicines that will expand options for patients in need of more effective therapies.”
By uniting scientists, clinicians and drug development experts together within MD Anderson, the institution’s Therapeutics Discovery division is designed to eliminate the bottlenecks slowing traditional drug discovery. Seamless integration with MD Anderson physicians allows Therapeutics Discovery to develop impactful cancer therapies inspired directly by patient needs and clinical insights.
Once a drug candidate is nominated, Sibylla and MD Anderson may consider further drug development, translational, and clinical activities to advance the candidate for patients in need.
Read this press release in the MD Anderson Newsroom.
-30-
Disclosure
MD Anderson has an institutional conflict of interest with Sibylla and will implement an Institutional Conflict of Interest Management and Monitoring Plan to manage this relationship.
About Sibylla Biotech
Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein. Through its protein folding simulation technology platform, Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
END
MD Anderson and Sibylla Biotech announce strategic collaboration to discover and develop small-molecule protein degraders
Sibylla’s PPI-FIT technology joins with MD Anderson’s drug development resources and expertise to create protein folding interfering degraders as cancer therapies
2024-06-12
ELSE PRESS RELEASES FROM THIS DATE:
Uncovering the nature of emergent magnetic monopoles
2024-06-12
Magnetic monopoles are elementary particles with isolated magnetic charges in three dimensions. In other words, they behave as isolated north or south poles of a magnet. Magnetic monopoles have attracted continuous research interest since physicist Paul Dirac’s first proposal in 1931. However, real magnetic monopoles have not yet been observed and their existence remains an open question. On the other hand, scientists have discovered quasi-particles that mathematically behave as magnetic monopoles in condensed ...
New study shows long-term effectiveness of gastric bypass in treating type 2 diabetes and obesity
2024-06-12
SAN DIEGO – June 12, 2024 -- Roux-en-Y gastric bypass, a type of weight-loss surgery, kept type 2 diabetes in remission for up to 15 years and most of the weight off for up to 20 years in one of the largest long-term studies of patients undergoing the procedure. The study* was presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting.
Researchers from Geisinger Medical Center in Danville, PA analyzed diabetes remission rates and weight-loss outcomes of 2,045 patients who had a gastric bypass at their center between 2001 and 2008 ...
Hokkaido University scientist recognized in award from the Royal Society of Chemistry
2024-06-12
The NSF Center for Molecularly Optimized Networks team, of which Professor Jian Ping Gong of the Faculty of Advanced Life Science and the Institute for Chemical Reaction Design and Discovery (WPI-ICReDD) at Hokkaido University is a member, has won a Horizon Prize from the Royal Society of Chemistry.
The Royal Society of Chemistry (RSC)’s Prizes portfolio is one of the oldest and most prestigious in the world, recognizing achievements by individuals, teams and organizations in advancing the chemical sciences. They reward those undertaking excellent work in the chemical sciences from across the world. The NSF Center for Molecularly Optimized Networks team, including Professor ...
Cocaine trafficking threatens critical bird habitats
2024-06-12
ITHACA, N.Y. – In addition to its human consequences, cocaine trafficking harms the environment and threatens habitats important to dozens of species of migratory birds, according to a new study.
Two-thirds of the areas that are most important to forest birds – including 67 species of migratory birds that breed in the U.S. and Canada and overwinter in Central America – are at increased risk from cocaine trafficking activities, according to the study, “Intersection of Narco-Trafficking, Enforcement and Bird Conservation ...
Humans are the elephant in the room where conservation is debated
2024-06-12
Humans are outsized actors in the world’s wild places where there are struggles to preserve and protect vital natural resources and animals, birds and plants. Yet people and their plus-sized footprint are rarely discussed in models seeking to predict and plan for trajectories of endangered species.
Sustainability scholars at Michigan State University in this week’s journal Nature Ecology and Evolution reveal the decades-long gaps in research and propose a new way of creating accurate visions for endangered species.
To map and predict species ...
No bones about it: 100-million-year-old bones reveal new species of pterosaur
2024-06-12
New Curtin University-led research has identified 100-million-year-old fossilised bones discovered in western Queensland as belonging to a newly identified species of pterosaur, which was a formidable flying reptile that lived among the dinosaurs.
Unearthed in 2021 by Kronosaurus Korner museum curator Kevin Petersen, the fossilised remains have been found to belong to Haliskia peterseni, a new genus and species of anhanguerian pterosaur.
Based on the shape of its skull, arrangement of teeth and shape of the shoulder bone, a research team led by ...
City of Hope CAR T cell therapy for advanced prostate cancer demonstrates positive results in phase 1 clinical trial
2024-06-12
City of Hope CAR T cell therapy for advanced prostate cancer demonstrates positive results in phase 1 clinical trial
• Trial results published today in Nature Medicine
• A phase 1b trial using the same CAR T cell therapy has opened
LOS ANGELES — Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope®, ...
Exposure to heat and cold in early life may affect development of white matter in the brain
2024-06-12
Barcelona, 12 June 2024 (EMBARGOED) -. Brain scans of more than 2,000 preadolescents suggests that early life exposure to heat and cold may have lasting effects on the microstructure of white matter in the brain, especially when living in poorer neighbourhoods. The study, published in Nature Climate Change, highlights the vulnerability of foetuses and children to extreme temperatures. This research has been led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the “la Caixa” Foundation, and IDIBELL, in collaboration with the Erasmus University Medical Center Rotterdam ...
The role of biodiversity in mitigating rapid loss of plant community stability in drylands during changing climate
2024-06-12
An international research team undertook a study of plants in the Mongolian grasslands to evaluate the stability of these plant communities over time. They specifically looked at how the dryness of the climate impacted the plant communities and determined that the stability of the plant communities decreased more rapidly in more arid areas. This research helps in the development of effective management strategies that promote stable ecosystems in a time of changing climate.
The research is published in the journal Global Change Biology on June 12, 2024.
Scientists know that climate change affects the way biodiversity influences the stability of plant ...
Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis
2024-06-12
About The Study: The observed difference in 90-day mortality between continuous versus intermittent infusions of β-lactam antibiotics did not meet statistical significance in the primary analysis. However, the confidence interval around the effect estimate includes the possibility of both no important effect and a clinically important benefit in the use of continuous infusions in this group of patients.
Quote from corresponding author Joel M. Dulhunty, M.D., Ph.D.:
“The BLING III trial provides important evidence to guide antibiotic management and improve outcomes for patients with sepsis. This large randomized clinical trial involved over ...
LAST 30 PRESS RELEASES:
How a common economic theory could help save endangered frogs
Stopping off-the-wall behavior in fusion reactors
Real-time cancer diagnostics and therapy through theranostics
Researchers confront new US and global challenges in vaccinations of adults
NCSA building stronger connections among observatories, astronomers
Latest advances in brain network models for medical applications: A comprehensive review highlights future potential
Jefferson Lab physicists named APS Fellows
Bias found when drug manufacturers fund clinical trials
The University of Texas at San Antonio is advancing space exploration as the lead of a multimillion-dollar DOE project
Gut hormones could hold the key to fighting fatty liver disease
Material informatics for the development of high-performance solid electrolytes in rechargeable batteries
Decoding bacterial genomes using single-cell genomics
Unexpected intellectual friendships, like Plato and Aristotle, are the secret of long-term innovation, finds prize-winning US academic
Aussies above 50 are living longer, while younger people are suffering
New polymer design breaks the tradeoff between toughness and recyclability
Tax, smoke-free legislation, and anti-smoking campaigns linked to smoking reduction
Targeting failure with new polymer technology to enhance sustainability
Stigma has a profound impact on health outcomes must be addressed
Has the affordable care act’s dependent coverage expansion benefited young adults diagnosed with cancer?
A new study reveals a key mechanism driving atherosclerosis in Hutchinson-Gilford Progeria Syndrome
HPV vaccination switch to 1-dose gender-neutral approach
Scurvy: Not just an 18th-century sailors’ disease
Scientists discover a secret to regulating our body clock, offering new approach to end jet lag
Impact of pollutants on pollinators, and how neural circuits adapt to temperature changes
Researchers seek to improve advanced pain management using AI for drug discovery
‘Neutron Nexus’ brings universities, ORNL together to advance science
Early release from NEJM Evidence
UMass Amherst astronomer leads science team helping to develop billion-dollar NASA satellite mission concept
Cultivating global engagement in bioengineering education to train students skills in biomedical device design and innovation
Life on Earth was more diverse than classical theory suggests 800 million years ago, a Brazilian study shows
[Press-News.org] MD Anderson and Sibylla Biotech announce strategic collaboration to discover and develop small-molecule protein degradersSibylla’s PPI-FIT technology joins with MD Anderson’s drug development resources and expertise to create protein folding interfering degraders as cancer therapies